Abstract
Microtubule affinity regulating kinase 4 (MARK4) is a serine/threonine kinase that plays a key role in tau phosphorylation and regulation of the mTOR pathway. Abnormal tau phosphorylation and dysregulation of the mTOR pathway are implicated in neurodegenerative and neurodevelopmental disorders.
Here, we report a novel gain-of-function variant in MARK4 in two siblings with childhood-onset neurodevelopmental disability and dysmorphic features.
The siblings carry a germline heterozygous missense MARK4 variant c.604T>C; p.Phe202Leu, located in the catalytic domain of the kinase, which they inherited from their unaffected, somatic mosaic mother. Functional studies show that this amino acid substitution has no impact on protein expression but instead increases the ability of MARK4 to phosphorylate tau isoforms found in the fetal and adult brain. The MARK4 variant also increases phosphorylation of ribosomal protein S6, indicating upregulation of the mTORC1 pathway.
This is the first study to link a germline monoallelic MARK4 variant to a childhood-onset neurodevelopmental disorder characterized by global developmental delay, intellectual disability, behavioral abnormalities, and dysmorphic features.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported in part by funding from BC Children's Hospital Foundation to establish the Rare Disease Discovery Hub and the Precision Health Initiative. S.E.T. holds a Tier 1 Canada Research Chair in Pediatric Precision Health and the Aubrey J. Tingle Professor of Pediatric Immunology. S.S. is funded by the University of British Columbia Four Year Doctoral Fellowship (4YF). M.V.S. is funded by the Vanier Canada Graduate Scholarship and the 4YF. The CAUSES Study investigators included Shelin Adam, Christele Du Souich, Alison Elliott, Anna Lehman, Jill Mwenifumbo, Tanya Nelson, Clara Van Karnebeek, and Jan Friedman; it was funded by Mining for Miracles, British Columbia Children's Hospital Foundation (grant number F15-01355) and Genome British Columbia (grant number F16-02276).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research study protocols were approved by The University of British Columbia Clinical Research Ethics Board (H15-00092 and H18-02853).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data supporting the findings of this study are available from the corresponding author, upon reasonable request.
Abbreviations
- DFG
- aspartate-phenylalanine-glycine
- EV
- Empty vector
- FMO
- Fluorescence minus one
- PHF
- paired helical filaments
- tGFP
- Turbo green fluorescent protein
- WT
- Wild-type
